Boltz has entered a strategic partnership with Takeda to deploy its biomolecular AI models across the Japanese pharmaceutical company’s discovery organisation, strengthening its position in the rapidly expanding field of AI-enabled drug design. The deal follows Boltz’s recent launch with $28 million in seed funding and an earlier partnership with Pfizer, marking another step in its push to embed foundation model technology into mainstream pharmaceutical R&D workflows. The collaboration will give Takeda scientists direct access to Boltz’s latest biomolecular models, designed to improve prediction of molecular structures and accelerate the identification of novel drug candidates. Embedding Foundation Models into Drug Discovery Workflows Under the agreement, Takeda will integrate Boltz’s platform into its internal research environment through user interfaces, APIs and agent-based integrations. This setup allows scientists from across disciplines, including machine learning, computational biology, medicinal chemistry and protein engineering, to interact with the models using natural language and structured computational tools. Boltz CEO Gabriele Corso said the aim is to make advanced biomolecular modelling more accessible and usable across discovery teams, enabling faster iteration and more informed decision-making in early-stage drug development. The partnership includes access to two core systems: BoltzMol-1, focused on small-molecule hit discovery, and BoltzProt-1, designed for protein engineering and design. Early Validation Across Multiple Targets Boltz has highlighted early validation results for its models across both small-molecule and biologics applications. BoltzMol-1 reportedly identified confirmed hits across six of ten tested targets while screening only 28 to 51 compounds per target. In parallel, BoltzProt-1 demonstrated improved performance in de novo nanobody design, achieving nearly triple the hit rate of its earlier generation model across benchmark targets. These results reflect growing industry interest in AI systems that can reduce experimental burden while increasing hit identification efficiency in early discovery. Integrating AI Directly into R&D Decision-Making A key feature of the collaboration is the integration of Boltz’s platform into Takeda’s existing discovery infrastructure via APIs and workflow tools. The system is designed to function alongside large language model agents, allowing researchers to run predictive and generative modelling tasks using natural language prompts. Boltz scientists will also collaborate directly with Takeda teams on selected programmes, supporting model fine-tuning for specific biological targets. While financial terms of the deal were not disclosed, Takeda will retain full ownership of any compounds generated using Boltz’s technology. Takeda Continues to Scale Its AI Strategy The agreement is part of Takeda’s broader expansion into AI-driven drug discovery. The company has recently also entered into a collaboration with Iambic, potentially worth more than $1.7 billion, focused on small-molecule discovery across oncology, gastrointestinal and inflammatory disease areas. Together, these partnerships highlight Takeda’s increasing reliance on external AI platforms to accelerate discovery across multiple therapeutic domains. A Growing Role for Foundation Models in Pharma R&D The Boltz–Takeda collaboration reflects a wider shift in pharmaceutical research, where foundation models are increasingly being embedded directly into discovery pipelines. Rather than acting as standalone tools, these systems are being integrated into day-to-day scientific workflows, enabling real-time prediction, design and prioritisation of drug candidates. As competition intensifies in AI-driven drug discovery, partnerships like this are likely to become a core mechanism for combining computational innovation with large-scale pharmaceutical development capabilities. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Biogen has agreed to acquire RayThera in a deal worth up to $1 billion, strengthening its position in immunology and adding a portfolio of small-molecule anti-inflammatory candidates to its development pipeline. The transaction includes an upfront payment alongside additional milestone-based payments tied to clinical and regulatory progress. It reflects Biogen’s continued push to diversify beyond its core neurology franchise into immune-mediated disease areas. Building Depth in Small-Molecule Immunology RayThera is a biotechnology company focused on small-molecule therapies targeting immune-driven conditions across multiple indications. The acquisition will bring several early-stage programmes into Biogen’s portfolio, including RayThera’s lead asset, which is expected to enter Phase I clinical development in early Q3 2026. Once the deal closes, Biogen will take full control of development, manufacturing, and global commercialisation responsibilities across the acquired pipeline. The assets are positioned to broaden Biogen’s immunology footprint at a time when large pharma companies are increasingly seeking diversification across inflammatory and autoimmune disease spaces. Biogen Targets Pipeline Expansion Beyond Neurology Biogen executive vice-president and head of development Priya Singhal said the acquisition enhances the company’s immunology strategy by adding new assets with potential to expand into additional disease areas. She noted that the deal supports Biogen’s long-term pipeline ambitions and accelerates the progression of lead candidates toward clinical development. RayThera CEO and co-founder Qing Dong described Biogen as a strong strategic fit given its global development capabilities in immunology, adding that the partnership would enable rapid advancement of the company’s programmes into clinical trials and beyond. Momentum in Early-Stage Dealmaking Continues RayThera recently completed a Series A financing round backed by OrbiMed Advisors, Foresite Capital, and TTM Capital, reflecting strong investor interest in early-stage immunology platforms. The acquisition also follows Biogen’s recent regulatory momentum, including the US FDA’s breakthrough therapy designation for salanersen (BIIB115), an investigational treatment for spinal muscular atrophy. Together, these developments highlight Biogen’s dual strategy of advancing internal neurology assets while actively expanding into adjacent therapeutic areas through targeted acquisitions. A Broader Shift Toward Early Immunology Bets The RayThera deal reflects a wider industry trend in which large biopharma companies are increasingly acquiring early-stage immunology assets to rebuild pipelines and offset future revenue pressure from mature franchises. With growing scientific validation and renewed investor interest in immune modulation, small-molecule approaches continue to attract deal activity alongside biologics and cell-based therapies. If successfully developed, RayThera’s portfolio could help reinforce Biogen’s long-term growth strategy in one of the most competitive areas of modern drug development. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Neurologist Compensation Report 2026 shows US neurologist earnings continuing on a familiar trajectory: modest growth, stable expectations, and little evidence of a return to strong upward momentum. Average total compensation now sits at approximately $341,000, with year-on-year growth of around 3%. That places neurology broadly in line with inflation-adjusted stability rather than meaningful real income expansion. This is no longer a growth story. It is a positioning story. Neurologist pay is increasingly defined by where you sit within a relatively stable distribution, rather than whether the overall average is rising. The key differentiator is no longer time in practice alone, but structure: workload mix, subspecialty focus, private work, and contract design. A Flat Growth Environment With Inflation-Level Gains Neurologists reported pay increases of roughly 3% in 2025, closely matching the wider physician average. While modest, this growth has kept pace with inflation, which stood at around 2.7% at the end of 2025. In real terms, this places neurology in a neutral zone: neither materially eroding nor significantly increasing purchasing power. As one healthcare consultancy director noted, the broader physician market is experiencing “a return to normalisation,” with compensation patterns stabilising after earlier volatility. The expectation now is not acceleration, but consistency. The underlying drivers remain familiar: Increased patient volumes and productivity Higher work relative value units (wRVUs) Incremental efficiency gains from digital systems and workflow improvements However, these drivers are producing stability rather than expansion. Where Neurologists Sit in the Earnings Distribution Neurology compensation is best understood as a distribution rather than a single benchmark. Most neurologists cluster around a central earnings band, with variation emerging at the edges based on role structure rather than tenure alone. Below the Main Range Neurologists in the lower earnings band are typically characterised by: Early consultant stage (0–3 years post-consultant) Predominantly salaried NHS-style or fixed contracts Limited private practice involvement Fewer subspecialty clinics or procedural weighting Standardised workload structures This group reflects entry into consultant-level practice without additional income layering. Around the Main Range The central band contains the majority of neurologists. This group typically includes: Established consultants (approximately 4–9 years post-consultant) Balanced inpatient and outpatient workloads Some additional sessions or limited private activity Standard productivity frameworks Stable, structured NHS-aligned contracts This is the functional core of neurology earnings in 2026. Importantly, movement within this band is often incremental rather than transformative. Above the Main Range Higher earners begin to separate through structure rather than experience alone. Common characteristics include: Higher subspecialty intensity (where applicable) Greater private practice exposure Additional clinical sessions beyond standard contracts Productivity-linked compensation structures Portfolio income streams such as medico-legal work, teaching, leadership roles, or advisory work At this level, earnings divergence is driven more by how work is structured than by seniority. The Negotiation Reality: Standardisation Over Individual Bargaining A significant majority of neurologists report limited negotiation leverage when entering or renewing contracts. Around 65% of neurologists said they were not highly assertive in salary negotiations, reflecting a broader shift toward standardised compensation frameworks. Healthcare employers increasingly favour structured pay systems over individual negotiation, with one compensation specialist noting that standardisation is now preferred to avoid internal disparities between physicians. The implication is clear: negotiation plays a smaller role than it once did, particularly in larger healthcare organisations. Perceived Value: The Fairness Gap Despite stable earnings, perceptions of fairness remain constrained. Only 45% of neurologists reported feeling fairly compensated for their work. While this is slightly improved compared to prior years, it still reflects a persistent disconnect between pay levels and perceived value. This gap is not purely financial. It is shaped by: Administrative workload Staffing pressures Clinical intensity Time constraints and burnout Contract structure and autonomy Even where compensation is objectively competitive, perceived fairness often diverges based on day-to-day working conditions. Broader Views: Are Doctors Underpaid? When asked about the profession more broadly, 52% of neurologists believe US physicians are underpaid. This represents a decline from previous sentiment but still indicates that more than half of respondents feel the profession is undervalued at a systemic level. The tension here is familiar: relative global comparisons suggest high earnings, but domestic cost pressures, workload intensity, and administrative burden continue to shape dissatisfaction. Pay Outlook: Stability Dominates Expectations Forward-looking expectations reinforce the theme of stability: 45% expect pay increases 45% expect flat pay 9% expect decreases The most notable figure here is not growth, but equilibrium: flat pay is now just as common as pay increases. This signals a market where upward movement is no longer guaranteed and where compensation trajectories are increasingly static unless role structure changes. Financial Adequacy: Mixed Outcomes When neurologists were asked whether their pay meets household financial needs: 24% said it exceeds needs 50% said it matches needs 26% said it falls short This distribution closely mirrors prior years and reinforces the idea of a stable but uneven system, where outcomes depend heavily on personal financial context and geography. Incentives and Performance-Based Pay Around 65% of neurologists are eligible for incentive-based compensation, most commonly linked to productivity metrics such as wRVUs. Performance pay is now a structural feature of neurology compensation rather than an exception. Key characteristics include: RVU-based productivity remains the dominant driver Quality metrics increasingly supplement bonus calculations Most physicians can influence bonus outcomes, at least partially Around 85% of physicians across specialties now have some form of performance-linked pay Importantly, incentive systems are generally viewed as more controllable than broader institutional evaluation frameworks, reinforcing their role as a behavioural lever in physician compensation design. Workload and Contract Structure Neurologists report working approximately 50 hours per week, consistent with prior years. Contract structures typically fall into three categories: Short-term contracts (≤1 year) Standard contracts (1–3 years) Long-term or “evergreen” annual renewal models There is little variation in working hours year-on-year, reinforcing the broader theme of structural stability across the specialty. Structural Pay Factors: The Real Differentiator Only around 34% of neurologists reported that metrics such as RVUs influence their base salary (not just bonuses), indicating that most base pay remains relatively fixed. However, where RVUs do influence base pay, compensation becomes more directly tied to output, reinforcing the importance of productivity within modern physician pay structures. This shift reflects a broader trend: compensation systems are increasingly designed around measurable output rather than purely time-served progression. Conclusion: Neurology Has Entered a Stable Distribution Era The 2026 data point to a clear conclusion. Neurology is no longer a specialty defined by rapid earnings progression or broad-based increases. Instead, it is defined by: Stable average growth (~3%) Strong clustering around a central earnings band Increasing reliance on structural differentiation Limited negotiation flexibility Persistent gaps in perceived fairness Flat expectations for future pay movement In short, neurology compensation is not accelerating. It is stabilising into a structured distribution where outcomes depend less on time in role, and more on how the role itself is built. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Oncologist Compensation Report 2026 paints a different picture from many other specialties. Unlike fields that have seen modest stability or slight gains, oncology has moved in the opposite direction. Average compensation fell by approximately 2% in 2025, bringing oncologists out of line with the broader physician trend of ~3% growth. This shift is not dramatic in absolute terms, but it is directionally important. Oncology is no longer tracking general physician pay growth. It is diverging from it. A Rare Downturn in Physician Compensation While most US physicians reported modest increases in earnings, oncologists experienced a slight decline in average total compensation. The typical oncologist now earns in the region of the mid-$300,000s (varying by subspecialty, setting, and private practice exposure), but the key story is not the absolute figure. It is the direction of travel. Where other specialties have stabilised or grown modestly, oncology has slipped. This puts it in a small group of specialties experiencing either flat or negative real movement in earnings. Even so, more than half of oncologists still expected some level of pay increase by year-end — highlighting a disconnect between expectations and realised outcomes. Inflation vs Earnings: A Negative Real Shift The broader physician market has broadly kept pace with inflation, which sat at around 2.7% at the end of 2025. Oncology did not. With a ~2% decline in average compensation, oncologists are effectively experiencing a double squeeze: Nominal earnings down Real earnings down even more sharply relative to inflation This creates a subtle but meaningful shift in financial pressure, particularly in high-intensity clinical roles. As one healthcare consultancy leader described the wider market, physician compensation is entering a “return to normalisation” phase. For oncology, however, that normalisation looks more like compression. Where Oncology Sits in the Earnings Hierarchy Oncology remains a relatively high-paying specialty in absolute terms, but it has lost upward momentum compared with procedural specialties. The top end of physician earnings continues to be dominated by fields such as orthopaedics, cardiology, radiology, and anaesthesiology. Oncology does not consistently sit in that top tier anymore. Instead, it occupies a middle-upper band where: Earnings are substantial but not accelerating Growth is uneven across practice types Structural factors matter more than seniority alone In practical terms, oncology compensation is increasingly shaped by: Institutional funding structures NHS-style productivity frameworks (in US analogues, hospital-employed RVU systems) Private practice mix Drug administration models and reimbursement environments This makes oncology highly sensitive to system-level financial pressures. Negotiation Power: Limited and Standardised A striking feature of oncology compensation is the lack of aggressive salary negotiation. Around 69% of oncologists reported they were not highly assertive in salary negotiations, with many indicating they had little or no opportunity to negotiate at all. This reflects a broader shift across medicine: Compensation is becoming standardised. Large healthcare organisations increasingly rely on fixed frameworks rather than individual bargaining, reducing variability between physicians in similar roles. As one healthcare compensation specialist noted, employers are moving toward standard compensation philosophies where negotiation is discouraged in favour of internal parity. The result is predictable pay structures — but reduced individual leverage. Perception vs Reality: The Fairness Paradox Despite the decline in earnings, oncologists report relatively strong perceptions of fairness compared with other specialties. Around 57% of oncologists felt fairly compensated as individuals. However, this is offset by a broader contradiction: 53% believe US physicians are underpaid overall That figure has increased significantly from prior years This creates a paradox where oncologists may feel relatively fairly treated within their own role, but still view the wider system as undervaluing medical labour. The disconnect is not purely financial. It reflects workload intensity, emotional burden, and systemic pressures unique to oncology practice. Pay Expectations: A Mixed Outlook Oncology shows a split outlook heading into the next cycle: 55% expect pay increases 39% expect flat pay 6% expect pay declines This distribution is important because it reveals optimism despite recent declines. However, the presence of a large flat-pay cohort reinforces a structural reality: oncology is not currently a high-growth compensation environment. Instead, it is stabilising around constrained budgets and reimbursement pressure. Incentive Pay and Productivity Dependence Approximately 75% of oncologists are eligible for incentive-based compensation. The dominant drivers of bonus pay include: Work Relative Value Units (wRVUs) Quality care metrics This places oncology firmly within the productivity-linked compensation model that now dominates US medicine. Across the profession, around 85% of physicians have some form of performance-linked pay. However, oncology is particularly exposed to the tension between: Volume-based productivity measures Quality and complexity of care delivery In oncology, higher complexity does not always translate cleanly into higher measurable productivity, creating friction in compensation models. Workload and Structural Intensity Oncologists report working approximately 52 hours per week, slightly above the physician average. This workload includes: Outpatient consultations Treatment planning Multidisciplinary coordination Administrative documentation On-call responsibilities in many settings The combination of high emotional intensity and administrative load contributes to ongoing concerns around burnout and sustainability. Despite this, workload has remained broadly stable year-on-year, suggesting limited relief from systemic pressure. Earnings Stability vs Structural Pressure While oncology compensation has not collapsed, it is increasingly shaped by structural constraints: Flat or declining real growth Reduced negotiation flexibility Heavy reliance on RVU-driven systems Reimbursement pressure (particularly in private practice) Institutional cost containment Even where earnings remain relatively high in absolute terms, the trajectory is the key issue. This is not a rapidly expanding earnings environment. It is a constrained one. The Bigger Picture: Oncology Is Entering a Compression Phase The 2026 data suggest oncology is moving into a distinct phase compared with many other specialties. Rather than growth or volatility, it is experiencing: Mild contraction in average pay Stable but uneven earnings distribution Increased dependence on institutional structures Persistent tension between workload and compensation Mixed but fragile optimism for future pay increases In short, oncology is not being revalued upward in the current market cycle. It is being held steady within a tightening system. Conclusion: A Specialty Defined by Pressure, Not Progress Oncology remains one of the most demanding specialties in medicine, both clinically and emotionally. However, its compensation trajectory in 2026 tells a clear story: Earnings are no longer rising in line with peers Real income has slipped slightly Structural constraints are becoming more dominant Future growth expectations are cautious rather than confident Where other specialties are stabilising, oncology is compressing. Not sharply, but persistently and in physician compensation, persistence matters more than headlines. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Endocrinologists in the US reported modest changes in compensation in 2025, but the broader picture is less about growth and more about stability within a constrained system. Average total compensation rose by around 4%, slightly above inflation, but the underlying structure of earnings continues to tighten. While some physicians saw gains, the specialty is increasingly defined by distribution rather than progression — where you sit within the range matters more than year-on-year movement. The 2026 earnings environment: modest growth, structural limits Across US physicians, average pay increases hovered around 3%, placing endocrinology slightly above trend at around 4%. Inflation pressures remain central to interpretation. Although nominal pay rose, real income gains are relatively limited once cost-of-living adjustments are accounted for. Industry analysts describe this phase as a “return to normalisation”, where compensation growth is no longer driven by broad sector expansion but by: Individual productivity (work relative value units / wRVUs) Efficiency improvements in clinical systems Local contract structures and payer mix In other words, income is increasingly engineered rather than organically rising. Where endocrinologists sit in the pay distribution Endocrinology earnings are best understood as a banded structure rather than a linear career ladder. Below the typical range This group sits beneath the main earnings cluster and typically reflects: Early consultant stage (0–3 years post-appointment) Predominantly salaried NHS-style or equivalent employed roles Limited private practice or additional sessions Lower exposure to high-yield subspecialty work This is not necessarily underperformance — it is structural positioning early in a career cycle. Around the main range Most endocrinologists sit within this central band, where earnings are defined less by ambition and more by system design. Typical characteristics include: Established consultants (approximately 4–9 years post-appointment) Standard outpatient endocrine caseloads (diabetes, thyroid, metabolic disease) Stable NHS or employed contracts Limited but consistent additional sessions or private activity Productivity aligned to institutional frameworks This is the functional core of endocrinology income in 2026. Above the main range Higher earners are not defined simply by seniority, but by structure and optionality. Common drivers include: Higher subspecialty intensity or niche clinic development Greater private practice exposure Additional clinical sessions beyond standard contracts Productivity-linked or performance-weighted compensation models Portfolio careers (teaching, medico-legal work, advisory roles) At this level, structure outweighs experience as the primary determinant of income. Satisfaction gap: income vs perceived value Despite relatively stable earnings, only a minority of endocrinologists report feeling fairly compensated. A key theme emerges: Income level does not reliably translate into perceived fairness. Across respondents: Just over 40% feel fairly compensated personally A majority believe the profession is underpaid overall This disconnect reflects a broader tension in modern medicine — rising workload complexity without proportional autonomy or reward. Workload pressure, administrative burden, and system constraints all shape perception as much as salary itself. Pay expectations: a flat but stable outlook Forward expectations reinforce the idea of a stabilising market rather than a growing one: Around half expect pay increases Roughly one-third expect flat pay A smaller minority expect pay declines Flat earnings are now nearly as common as growth, signalling a plateau phase in compensation cycles. This is particularly relevant for private practice physicians exposed to reimbursement pressures, especially from public payer systems. The role of productivity: RVUs dominate Across endocrinology, compensation is increasingly tied to measurable output. Among those eligible for incentive pay, the most important drivers include: Work Relative Value Units (wRVUs) Quality metrics tied to clinical outcomes Approximately three-quarters of endocrinologists have access to some form of bonus structure, and most systems rely heavily on productivity measurement. This reflects a wider shift across US medicine: Around 85% of physicians now have some form of productivity-linked pay component. The implication is clear — compensation is becoming algorithmic in nature, tied to output metrics rather than tenure or seniority. Workload reality: stable hours, rising intensity Endocrinologists report working around 48 hours per week, broadly consistent year-on-year. However, this figure masks underlying complexity: Clinical time remains steady Administrative and documentation burden continues to rise Patient complexity is increasing, particularly in metabolic disease and diabetes management The result is a system where time remains constant, but intensity increases. Gender and structural disparities The report continues to highlight a persistent gender pay gap across medicine, with male physicians earning significantly more on average. Key points: Gap remains over $100,000 on average Little improvement year-on-year More pronounced among specialists than primary care physicians The underlying issue is not solely pay structure, but also: Bonus allocation differences Negotiation disparities Role segmentation within organisations Despite growing awareness, the trend remains largely unchanged. Final outlook: a mature, constrained earnings model Endocrinology in 2026 is no longer characterised by rapid earnings growth or clear upward mobility. Instead, it reflects a mature compensation system defined by: Stable but compressed pay growth High dependence on productivity metrics Strong variation based on role structure rather than seniority Persistent dissatisfaction despite moderate income levels The most important shift is conceptual: Endocrinology earnings are no longer defined by progression. They are defined by position within a stable but uneven distribution. Source: Medscape Endocrinologist Compensation Report 2026 (May 2026) Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Ob/Gyn Compensation Report 2026 shows obstetricians and gynaecologists earning approximately $390,000 in average total compensation. While compensation increased by roughly 5% during 2025, this is no longer simply a growth story. It is a positioning story. Ob/Gyn earnings are best understood by where you sit relative to the $390,000 benchmark, not whether the average is rising. Most variation now comes from workload structure, procedural intensity, and practice model rather than experience alone. Ob/Gyn compensation sits at approximately $390,000 on average The Medscape 2026 data places Ob/Gyn compensation at roughly $390,000, positioning the specialty firmly above many medical specialties but below the highest-paid procedural disciplines. What this means in real terms: This is now the baseline reference point for Ob/Gyn. Anything meaningfully below $390,000 places you under the specialty average. Anything meaningfully above it places you within the higher-earning segment of the profession. So the key question becomes: Are you above or below the $390,000 Ob/Gyn anchor point? Because this is now the effective centre of gravity for the specialty. Below the $390,000 range This group sits under the main Ob/Gyn earnings cluster. This typically reflects: Lower procedural or surgical volumes Predominantly employed or salaried positions Limited private practice exposure Reduced access to higher-margin subspecialist work What this means in real terms: You remain within normal Ob/Gyn compensation ranges, but you sit below the current specialty average of $390,000. Around the $390,000 range This is where a large proportion of Ob/Gyn physicians sit. Earnings here are shaped by: Consistent clinic and procedural activity Standard consultant productivity levels Mixed employed and private practice work Typical RVU-driven compensation structures This is the functional centre of Ob/Gyn earnings in 2026. Above the $390,000 range This is where compensation begins to separate from the main distribution. Higher earners are typically characterised by: Greater surgical and procedural intensity Stronger private practice exposure Subspecialist expertise Additional revenue streams and productivity incentives At this level, structure matters more than tenure. Only 53% of Ob/Gyns feel fairly compensated Despite average compensation reaching $390,000, only 53% of Ob/Gyns report feeling fairly compensated. Meanwhile, 71% believe physicians in the US are underpaid overall. This highlights a significant disconnect. High income does not automatically translate into perceived fairness. What this means for you: Two Ob/Gyns earning similar compensation can experience very different realities depending on: Call requirements Delivery volume Administrative burden Staffing support Work-life balance Even with rising compensation, satisfaction remains uneven across the specialty. Expectations point to a stabilising market The report shows: 37% expect pay increases 43% expect flat pay 20% expect pay decreases What this means in real terms: Flat compensation is now the most common expectation. The strong post-pandemic growth period appears to be moderating. Future earnings progression is becoming less predictable and more dependent on individual practice circumstances. What this means for you by experience level If you are early career (0–3 years post-consultant) At this stage, $390,000 is not where most Ob/Gyns begin. Positioning matters more than absolute compensation. If you are: Below $390,000, you are still building procedural volume and productivity Around $390,000, you are progressing towards typical specialty earnings relatively quickly Above $390,000, you are likely operating in a high-volume or strong procedural pathway early Key point: Early career outcomes are heavily influenced by procedural exposure and contract structure. If you are mid-career (4–9 years) This is where many physicians converge around the $390,000 benchmark. What the report implies: Most Ob/Gyns cluster around the average Earnings divergence begins through productivity and procedural intensity Practice structure becomes increasingly important If you are: Below $390,000, you sit beneath the specialty earnings centre Around $390,000, you are tracking typical Ob/Gyn outcomes Above $390,000, you are entering the higher-performing earnings segment Key insight: This is where structural factors begin to outweigh experience. If you are established (10–19 years) At this stage, $390,000 becomes a dividing line rather than simply a benchmark. What the report suggests: A stable earnings core remains around the average. A higher-income tier emerges through: Increased surgical volume Subspecialisation Private practice activity Leadership responsibilities If you are: Below $390,000, you are under the current earnings anchor Around $390,000, you remain aligned with the core distribution Above $390,000, you are capturing a disproportionate share of specialty earnings Key point: The financial gap between compensation bands becomes increasingly meaningful. If you are senior (20+ years) At the senior level, compensation tends to split into two distinct pathways: Stable earnings around the $390,000 benchmark Continued progression beyond it through scale, reputation, procedural intensity, and private practice exposure The difference is no longer driven by years of experience. It is driven by structure. The workload factor cannot be ignored Ob/Gyn physicians reported working an average of 52 hours per week, compared with 49 hours across physicians generally. This places Ob/Gyn among the heavier workload specialties. The implication is important: The compensation discussion cannot be separated from workload. The relatively modest proportion of physicians who feel fairly compensated may reflect not just pay levels, but the demands required to earn them. The core message of the 2026 report The Medscape 2026 Ob/Gyn data can be reduced to three anchors: Ob/Gyn averages approximately $390,000 Only 53% feel fairly compensated More physicians expect flat pay than pay increases Taken together, the structure is clear: Ob/Gyn remains a well-compensated specialty where $390,000 is the central reference point, but future earnings growth is becoming less certain and increasingly dependent on how a physician is positioned within the distribution. Summary If you are an Ob/Gyn reading this report, the key question is not whether the specialty pays well. It clearly does. The real question is: Am I below, around, or above the $390,000 benchmark? And is my position shaped by procedural volume, private practice exposure, productivity metrics, or structural constraints? Because the report makes one thing clear: Ob/Gyn compensation is increasingly defined not by average growth, but by where you sit within the distribution. Source Medscape Ob/Gyn Compensation Report 2026. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Ophthalmologist Compensation Report 2026 shows ophthalmology remains one of the highest-paying physician specialties, with average compensation rising sharply during 2025. Ophthalmologists reported compensation growth of approximately 9% year-over-year, making the specialty one of the strongest performers in the survey, with average total compensation sitting at approximately $464,000. This is not simply a high-income specialty. It is a specialty where earnings growth has returned. But as with most mature physician markets, the biggest differences are no longer created by experience alone. They are created by where you sit relative to the ophthalmology earnings benchmark and the structure of your practice. Ophthalmology compensation continues to outperform most specialties The Medscape 2026 data places ophthalmology among the strongest-performing specialties for compensation growth. A 9% increase significantly exceeded: The physician average of 3% Core inflation of 2.7% Most non-procedural specialties What this means in real terms: Ophthalmology is not simply maintaining earnings. It is expanding them. But averages only tell part of the story. The more important question is: Where do you sit within the ophthalmology earnings distribution? Because procedural volume, surgery centre ownership and private activity increasingly determine outcomes. Below the ophthalmology earnings range This group sits below the specialty's main compensation cluster. This typically reflects: Lower procedural volumes Primarily employed or salaried positions Limited private practice exposure Reduced access to surgical revenue streams What this means in real terms: You may still be earning well relative to many physician specialties. However, you sit below the earnings level currently being generated by the broader ophthalmology market. Around the ophthalmology earnings range This is where much of the specialty sits. Compensation here is typically driven by: Consistent patient volume Regular procedural activity Standard productivity levels A balanced mix of clinical and surgical work This represents the functional centre of ophthalmology earnings in 2026. Above the ophthalmology earnings range This is where earnings begin to separate from the wider distribution. Higher earners are often characterised by: High surgical throughput Greater procedure volumes Strong private practice exposure Ownership interests in ambulatory surgery centres Efficient productivity models At this level, practice structure becomes a more important driver than seniority. Only 49% of ophthalmologists feel fairly compensated Despite strong compensation growth, only 49% of ophthalmologists reported feeling fairly compensated. This is an important finding. Higher earnings do not automatically translate into higher satisfaction. What this means for you: Two ophthalmologists earning similar amounts may have very different experiences depending on: Administrative burden Workload intensity Staffing support Productivity expectations Practice ownership structure Compensation and satisfaction remain separate issues. Expectations suggest continued optimism The report shows: 45% expect compensation increases 39% expect flat pay 17% expect compensation declines What this means in real terms: The outlook is considerably stronger than a year ago. The proportion expecting increases rose from 27% to 45%, while expectations of pay reductions almost halved. Growth remains the most likely outcome, although not universally. Incentives are increasingly tied to productivity Among ophthalmologists eligible for incentive compensation: Number of procedures RVU generation were the leading bonus drivers. What this means: Compensation is becoming increasingly linked to measurable output. This creates significant upside potential for high-volume practitioners but can widen earnings gaps within the specialty. What this means for you by experience level If you are early career (0–3 years post-consultant) At this stage, growth potential matters more than current earnings. If you are: Below the specialty range, you are still building surgical volume and productivity Around the range, you are progressing in line with typical ophthalmology outcomes Above the range, you have likely entered a high-volume or private-practice pathway early Key point: Early-career progression is heavily influenced by procedural opportunities. If you are mid-career (4–9 years) This is where earnings often begin to separate. What the report suggests: Most ophthalmologists cluster around the specialty average Higher earners increasingly differentiate through surgery and private activity If you are: Below the range, you sit beneath the specialty's earnings centre Around the range, you reflect typical ophthalmology outcomes Above the range, you are benefiting from productivity and structural advantages Key insight: This is where business structure starts to matter as much as clinical experience. If you are established (10–19 years) At this stage, earnings divergence becomes more visible. What the report shows: A stable middle exists, but a higher-income tier emerges for practitioners with stronger procedural and ownership exposure. If you are: Below the range, you sit below the specialty benchmark Around the range, you align with the core distribution Above the range, you are capturing a disproportionate share of ophthalmology income Key point: The financial gap between groups becomes increasingly meaningful. If you are senior (20+ years) At the senior level, earnings typically split into two pathways: Stable earnings supported by established practice activity, or continued growth driven by surgery, ownership and private practice scale. The distinction is no longer based on experience. It is based on structure. The core message of the 2026 report The Medscape 2026 ophthalmology data can be reduced to three anchors: Compensation rose approximately 9% in 2025 49% feel fairly compensated 45% expect further earnings growth Taken together, the picture is clear: Ophthalmology remains one of the strongest-performing physician specialties financially. But while overall earnings are growing, individual outcomes are increasingly determined by procedural activity, productivity and practice structure. Summary If you are an ophthalmologist reading this report, the key question is not whether compensation is increasing. It is the more important question is: Am I positioned to benefit from that growth? Because the report makes one thing clear: Ophthalmology is experiencing one of the strongest compensation expansions in medicine, but your place within the distribution is increasingly determined by procedures, productivity and ownership rather than experience alone. Source Medscape Ophthalmologist Compensation Report 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Emergency Medicine Physician Compensation Report 2026 shows emergency medicine remains one of the higher-paying physician specialties, with average total compensation sitting at approximately $421,000. This includes base salary, bonuses, and additional income such as productivity incentives and other compensation arrangements. Emergency medicine earnings are best understood by where you sit relative to the $421,000 benchmark, not whether the average is rising. Most variation now comes from structure, workload intensity, and compensation models rather than experience alone. Emergency medicine compensation sits at approximately $421,000 on average The Medscape 2026 data places emergency medicine physicians at roughly $421,000 in average total compensation, following an estimated 8% increase during 2025. What this means in real terms: This is now the baseline reference point for emergency medicine. Anything meaningfully below $421,000 places you under the specialty average. Anything meaningfully above it places you in the upper earnings band of emergency medicine. So the key question becomes: Are you above or below the $421,000 emergency medicine anchor point? Because this is now the effective centre of gravity for the specialty. Below the $421,000 range This group sits under the main emergency medicine earnings cluster. This typically reflects: Lower productivity-based compensation Reduced shift volume or flexible scheduling arrangements Organisations with more conservative compensation structures What this means in real terms: You are still within emergency medicine norms, but you are below the current specialty average of $421,000. Around the $421,000 range This is where most emergency medicine physicians sit. Earnings here are shaped by: Standard emergency department workloads Typical productivity expectations Conventional employed physician compensation models This is the functional centre of emergency medicine earnings in 2026. Above the $421,000 range This is where earnings begin to separate from the main distribution. Higher earners are typically characterised by: Higher patient volumes and productivity metrics Greater exposure to RVU-based compensation systems Additional shifts, leadership responsibilities, or supplementary work At this level, structure matters more than tenure. Only 57% of emergency medicine physicians feel fairly compensated Despite a $421,000 average income, only 57% of emergency medicine physicians report feeling fairly compensated. At the same time, 61% believe physicians in the United States are underpaid overall. This highlights a key disconnect. High absolute income does not automatically translate into perceived fairness. What this means for you: Two emergency medicine physicians earning similar incomes can experience very different realities depending on shift intensity, staffing levels, administrative pressures, and workplace support. Even in a specialty earning more than $400,000 annually on average, satisfaction is not evenly distributed. Expectations point to a stable but uneven market The report shows: 45% expect pay increases 40% expect flat pay 16% expect a decrease What this means in real terms: Growth expectations remain positive overall, but flat pay remains a significant outcome for a large proportion of physicians. So even in a specialty anchored at $421,000, future earnings progression is not guaranteed. What this means for you by experience level If you are early career (0–3 years post-residency) At this stage, $421,000 is not where most emergency medicine physicians begin. Positioning matters more than the absolute number. If you are: Below $421,000, you are still building productivity and experience Around $421,000, you are reaching typical specialty earnings relatively early Above $421,000, you are already operating within a higher-output compensation model Key point: Early career outcomes are driven more by shift structure and productivity than years of service. If you are mid-career (4–9 years) This is where earnings typically stabilise around the $421,000 anchor. What the report implies: Most physicians converge around the average. Divergence begins through workload intensity, RVU performance, and additional responsibilities. If you are: Below $421,000, you are under the emergency medicine earnings centre of gravity Around $421,000, you are tracking typical specialty outcomes Above $421,000, you are operating in a higher productivity segment Key insight: This is where compensation structure begins to outweigh experience. If you are established (10–19 years) At this stage, $421,000 becomes a dividing line rather than a benchmark. What the report shows: A stable earnings cluster remains around the average. A higher tier emerges through leadership roles, productivity incentives, and expanded responsibilities. If you are: Below $421,000, you are under the current emergency medicine earnings anchor Around $421,000, you remain aligned with the core distribution Above $421,000, you are capturing a disproportionate share of specialty income Key point: The financial gap between earnings bands becomes increasingly meaningful. If you are senior (20+ years) At the senior level, earnings tend to follow two pathways: Stabilised compensation around $421,000 or continued progression above it through leadership, productivity-based compensation, and additional revenue opportunities. The difference is no longer primarily experience-based. It is structural. The role of productivity is becoming more important The report highlights a notable shift. Around one-third of emergency medicine physicians now report that measurable productivity metrics such as RVUs influence their base compensation, not just bonus payments. What this means: Future earnings growth is increasingly linked to output and measurable activity rather than fixed salary progression. For many physicians, compensation is becoming more performance-driven. The core message of the 2026 report The Medscape 2026 emergency medicine data can be reduced to three anchors: Emergency medicine averages approximately $421,000 57% feel fairly compensated Most physicians expect either modest growth or flat earnings Taken together, the structure is clear: Emergency medicine is a high-income specialty where $421,000 is the central reference point, but not everyone sits at it, and not everyone moves beyond it. Summary If you are an emergency medicine physician reading this report, the key question is not whether the specialty pays well. It clearly does. The real question is: Am I below, around, or above the $421,000 benchmark? And is my position shaped by productivity, compensation structure, leadership responsibilities, or workload intensity? Because the report makes one thing clear: Emergency medicine earnings are rising, but your position within the distribution defines your outcome. Source Medscape Emergency Medicine Physician Compensation Report 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Family Physician Compensation Report 2026 shows family medicine remains one of the largest and most important physician specialties, with average total compensation sitting at approximately $288,000. This includes base salary, bonus payments, and additional income such as productivity incentives and profit-sharing arrangements. Family medicine earnings are best understood by where you sit relative to the $288,000 benchmark, not whether the average is rising. Most variation now comes from compensation structure, productivity expectations, and practice environment rather than experience alone. Family medicine compensation sits at approximately $288,000 on average The Medscape 2026 data places family physicians at roughly $288,000 in average total compensation, following a modest 2% increase during 2025. What this means in real terms: This is now the baseline reference point for family medicine. Anything meaningfully below $288,000 places you under the specialty average. Anything meaningfully above it places you in the upper earnings band of family medicine. So the key question becomes: Are you above or below the $288,000 family medicine anchor point? Because this is now the effective centre of gravity for the specialty. Below the $288,000 range This group sits under the main family medicine earnings cluster. This typically reflects: Lower productivity-based compensation Reduced patient volume or flexible schedules Practice settings with more limited bonus opportunities What this means in real terms: You are still within family medicine norms, but you are below the current specialty average of $288,000. Around the $288,000 range This is where most family physicians sit. Earnings here are shaped by: Consistent patient volumes Standard primary care productivity expectations Typical employed physician compensation structures This is the functional centre of family medicine earnings in 2026. Above the $288,000 range This is where earnings begin to separate from the main distribution. Higher earners are typically characterised by: Higher patient throughput and productivity Stronger RVU-based compensation performance Additional responsibilities, leadership roles, or supplementary income streams At this level, structure matters more than tenure. Only 54% of family physicians feel fairly compensated Despite a $288,000 average income, only 54% of family physicians report feeling fairly compensated. Meanwhile, 58% believe physicians in the United States are underpaid overall. This highlights a key disconnect. Higher earnings do not automatically translate into perceived fairness. What this means for you: Two family physicians earning similar incomes can experience very different realities depending on patient complexity, administrative workload, staffing support, and organisational pressures. Even within a relatively stable specialty, satisfaction is unevenly distributed. Expectations point to a stable but uneven market The report shows: 45% expect pay increases 39% expect flat pay 16% expect a decrease What this means in real terms: Although pay growth remains possible, flat compensation is now nearly as common as increases. So even in a specialty anchored at $288,000, future earnings progression is inconsistent rather than guaranteed. What this means for you by experience level If you are early career (0–3 years post-residency) At this stage, $288,000 is not where most family physicians begin. Positioning matters more than the absolute number. If you are: Below $288,000, you are still building productivity and patient panels Around $288,000, you are approaching typical specialty earnings relatively early Above $288,000, you are operating within a higher-output compensation model Key point: Early career outcomes are driven more by practice structure and patient volume than years of service. If you are mid-career (4–9 years) This is where earnings typically stabilise around the $288,000 anchor. What the report implies: Most physicians converge around the average. Divergence begins through productivity, bonus structures, and organisational models. If you are: Below $288,000, you are under the family medicine earnings centre of gravity Around $288,000, you are tracking typical specialty outcomes Above $288,000, you are operating in a higher productivity segment Key insight: This is where compensation structure begins to outweigh experience. If you are established (10–19 years) At this stage, $288,000 becomes a dividing line rather than a benchmark. What the report shows: A stable earnings cluster remains around the average. A higher tier emerges through productivity incentives, leadership opportunities, and enhanced compensation models. If you are: Below $288,000, you are under the current family medicine earnings anchor Around $288,000, you remain aligned with the core distribution Above $288,000, you are capturing a disproportionate share of specialty income Key point: The financial gap between earnings bands becomes increasingly meaningful. If you are senior (20+ years) At the senior level, earnings tend to follow two pathways: Stabilised compensation around $288,000 or continued progression above it through leadership responsibilities, productivity incentives, and additional revenue opportunities. The difference is no longer primarily experience-based. It is structural. Productivity is becoming increasingly important The report highlights an important shift. 36% of family physicians now report that measurable metrics such as RVUs influence their base pay, not just bonus payments. What this means: Compensation is becoming increasingly tied to measurable activity and productivity. Future earnings growth may depend less on tenure and more on the ability to generate and sustain clinical output. The core message of the 2026 report The Medscape 2026 family medicine data can be reduced to three anchors: Family medicine averages approximately $288,000 54% feel fairly compensated Most physicians expect either modest growth or flat earnings Taken together, the structure is clear: Family medicine is a stable primary care specialty where $288,000 is the central reference point, but not everyone sits at it, and not everyone moves beyond it. Summary If you are a family physician reading this report, the key question is not whether the specialty provides a solid income. It clearly does. The real question is: Am I below, around, or above the $288,000 benchmark? And is my position shaped by productivity, compensation design, patient volume, or structural constraints? Because the report makes one thing clear: Family medicine earnings are stable, but your position within the distribution defines your outcome. Source Medscape Family Physician Compensation Report 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Pediatrician Compensation Report 2026 shows paediatrics remains the lowest-paying specialty in the compensation survey, with average total compensation sitting at approximately $266,000. This includes base salary, bonus, and additional income such as productivity incentives and other compensation-related earnings. Paediatrician earnings are best understood by where you sit relative to this $266,000 benchmark, not whether the average is rising. Most variation now comes from structure, not seniority alone. Pediatrician compensation sits at approximately $266,000 on average The Medscape 2026 data places paediatricians at roughly $266,000 in average total compensation, making it the lowest-paying specialty included in the report. What this means in real terms: This is now the baseline reference point for paediatrics. Anything meaningfully below $266,000 places you under the specialty average. Anything meaningfully above it places you in the upper earnings band of paediatrics. So the key question becomes: Are you above or below the $266,000 paediatrician anchor point? Because this is now the effective centre of gravity for the specialty. Below the $266,000 range This group sits under the main paediatric earnings cluster. This typically reflects: Predominantly salaried employment models Lower access to productivity-based incentives Reduced opportunities for additional paid clinical activity What this means in real terms: You are still within paediatric norms, but you are below the current specialty average of $266,000. Around the $266,000 range This is where most paediatricians sit. Earnings here are shaped by: Standard clinic-based patient volumes Typical productivity and bonus structures Conventional employed physician arrangements This is the functional centre of paediatric earnings in 2026. Above the $266,000 range This is where earnings begin to separate from the main distribution. Higher earners are typically characterised by: Stronger productivity performance Additional leadership or administrative responsibilities Greater access to incentive compensation and supplementary income streams At this level, structure matters more than seniority. Only 45% of paediatricians feel fairly compensated Despite a $266,000 average, just 45% of paediatricians report feeling fairly compensated. This is among the lowest satisfaction scores in the report. What this means for you: High relative workload and responsibility do not necessarily translate into perceptions of fair reward. Two paediatricians on similar earnings can experience very different realities depending on patient volumes, administrative burden, staffing support, and work-life balance. Even within a lower-paying specialty, compensation satisfaction is not evenly distributed. Most paediatricians still believe medicine is underpaid The report shows: 45% feel fairly compensated 60% believe physicians are underpaid overall 39% say their income falls short of family financial needs What this means in real terms: Paediatrics faces a wider perception gap than many higher-paying specialties. Income levels alone do not explain how doctors evaluate compensation. Workload intensity and financial expectations remain major factors. Expectations point to a flat market The report shows: 33% expect pay increases 47% expect flat pay 19% expect a decrease What this means in real terms: Flat pay is now the dominant expectation. Growth is no longer the central narrative. So even in a specialty anchored at $266,000, future earnings progression appears inconsistent and limited. What this means for you by experience level If you are an early career physician (0–3 years post-training) At this stage, $266,000 is not where most paediatricians begin. Positioning matters more than the absolute level. If you are: Below $266,000, you are still building experience and productivity Around $266,000, you are approaching typical specialty earnings Above $266,000, you are progressing faster than the specialty average Key point: Early-career outcomes are influenced more by employer structure and productivity opportunities than tenure. If you are mid-career (4–9 years) This is where earnings typically stabilise around the $266,000 anchor. What the report implies: Most paediatricians converge around the average. Variation begins to emerge through productivity models, leadership responsibilities, and supplementary income opportunities. If you are: Below $266,000, you are under the paediatric earnings centre of gravity Around $266,000, you are tracking typical specialty outcomes Above $266,000, you are in the higher-performing segment of the specialty Key insight: This is where structure begins to outweigh experience. If you are established (10–19 years) At this stage, $266,000 becomes a dividing line rather than a benchmark. What the report shows: A stable core cluster remains around the average. A smaller higher-income group emerges through productivity, management responsibilities, and additional revenue streams. If you are: Below $266,000, you are under the current paediatric earnings anchor Around $266,000, you are aligned with the core distribution Above $266,000, you are capturing a disproportionate share of specialty income Key point: The financial gap between earnings bands becomes increasingly meaningful. If you are senior (20+ years) At the senior level, earnings are split into two pathways: Stabilised earnings around $266,000 or continued progression above it through leadership, productivity, and supplementary income opportunities. The difference is no longer experience-based. It is structural. The core message of the 2026 report The Medscape 2026 paediatrician data can be reduced to three anchors: Paediatrics averages approximately $266,000 Only 45% feel fairly compensated Nearly half expect flat pay moving forward Taken together, the structure is clear: Paediatrics remains one of medicine's most important specialties, but it also sits at the bottom of the compensation rankings, with earnings anchored around $266,000 and limited expectations for future growth. Summary If you are a paediatrician reading this report, the key question is not whether compensation is increasing. The data suggests it largely is not. The real question is: Am I below, around, or above the $266,000 benchmark? And is my position shaped by productivity, organisational structure, or limited access to higher-paying opportunities? Because the report makes one thing clear: paediatrician earnings have flattened, and your position within the distribution defines your outcome. Source Medscape Pediatrician Compensation Report 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Gastroenterologist Compensation Report 2026 shows gastroenterology remains one of the highest-paying physician specialties, with average compensation reaching $530,000 in 2025. Gastroenterologists reported moderate compensation growth of around 3% year-over-year, placing the specialty firmly in the upper tier of physician earnings. This is not a stagnant high-income specialty. It is a high-income specialty where earnings have resumed steady growth after a flat period. But as with most mature procedural specialties, the key differentiator is no longer baseline income. It is where you sit within the earnings distribution and how your practice is structured. Gastroenterology compensation continues to sit in the upper tier of medicine The Medscape 2026 data confirms gastroenterology remains among the top-earning specialties in US medicine. A 3% increase aligns with broader physician compensation trends, but the absolute level of earnings remains structurally high at $530,000 on average. What this means in real terms: Gastroenterology is not a marginal high earner. It is consistently positioned in the upper compensation band due to procedural revenue and demand-driven workload. But averages conceal meaningful internal variation. The more relevant question becomes: Where do you sit within the gastroenterology earnings distribution? Because procedural volume, subspecialisation, and practice ownership increasingly determine outcomes. Below the gastroenterology earnings range This group typically sits below the specialty average. This is often associated with: Lower procedural volume Employed or hospital-based roles Limited private practice exposure Reduced endoscopy throughput Less control over scheduling and case mix What this means in real terms: You are still likely earning strong physician-level income. But you are not participating fully in the procedural upside that defines the upper end of gastroenterology earnings. Around the gastroenterology earnings range This represents the core distribution of the specialty. Most gastroenterologists sit here, with compensation driven by: Consistent endoscopy volume Standard procedural throughput Balanced inpatient and outpatient work Moderate productivity (RVU-aligned output) Typical employed or group practice models This is the functional centre of gastroenterology compensation in 2026. Above the gastroenterology earnings range This is where earnings begin to materially diverge. Higher earners are typically characterised by: High-volume procedural practice Increased endoscopy and intervention frequency Strong private practice exposure Ownership stakes in ambulatory surgery/endoscopy centres Optimised scheduling and efficiency models At this level, structure matters more than tenure. Experience alone is not the driver. Productivity architecture is. Only 54% of gastroenterologists feel fairly compensated Despite strong headline earnings, just over half of gastroenterologists report feeling fairly compensated. This creates a clear disconnect between absolute income and perceived value. What this means in practice: Two gastroenterologists earning similar salaries may experience very different realities depending on: Case volume pressure Administrative burden Staffing and anaesthesia support Call intensity Ownership vs employed structure Compensation and satisfaction remain structurally decoupled. Expectations show cautious but stable optimism The report highlights mixed forward expectations: 38% expect compensation increases 44% expect flat pay 18% expect declines What this means in real terms: The majority of gastroenterologists are not expecting rapid earnings acceleration. Instead, the market is stabilising after prior volatility, with modest growth expected at best. Incentives are strongly tied to procedural output Among gastroenterologists eligible for bonus structures, compensation is primarily driven by: RVU generation Procedural volume (endoscopy activity) What this means: Income upside is increasingly linked to measurable throughput. This benefits high-volume practitioners but widens dispersion between different practice models. What this means for you by experience level If you are early career (0–3 years post-consultant) At this stage, earnings are shaped more by exposure than efficiency. If you are: Below the range → limited procedural access or slower ramp-up Around the range → typical training-to-practice transition outcomes Above the range → early access to high-volume lists or favourable group structure Key point: Early career success is primarily determined by procedural opportunity. If you are mid-career (4–9 years) This is where earnings divergence begins to accelerate. What the report suggests: Most gastroenterologists consolidate around the average, but high earners begin to separate through: Procedure density Private practice integration Efficiency in throughput If you are: Below the range → limited procedural growth or constrained systems Around the range → standard progression trajectory Above the range → benefiting from high-volume practice design Key insight: Structure starts to matter as much as clinical experience. If you are established (10–19 years) At this stage, earnings become increasingly path-dependent. What the report shows: A stable core distribution exists, but a higher-income tier is clearly driven by procedural intensity and ownership. If you are: Below the range → constrained by system or volume limits Around the range → aligned with typical specialty earnings Above the range → capturing disproportionate procedural revenue share Key point: Income divergence becomes financially meaningful. If you are senior (20+ years) At senior level, outcomes typically split into two groups: Stable, salaried or group-based earnings High-output procedural or ownership-driven earnings Experience alone no longer predicts income. Practice structure does. The core message of the 2026 report The Medscape Gastroenterology Compensation Report 2026 can be summarised in three anchors: Average compensation: $530,000 54% feel fairly compensated 38% expect earnings growth Taken together: Gastroenterology remains one of the highest-earning specialties in medicine. But within-specialty outcomes are increasingly determined by: Procedural volume Productivity systems Ownership exposure Practice structure Summary If you are a gastroenterologist reading this, the key question is not whether the specialty pays well. It is whether your position within the system allows you to benefit from that compensation structure. Because the report makes one thing clear: Gastroenterology is a high-income specialty with stable growth, but earnings dispersion is increasingly determined by procedure volume and practice design rather than experience alone. Source Medscape Gastroenterologist Compensation Report 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape Psychiatrist Compensation Report 2026 shows psychiatry remains one of the better-paid non-procedural physician specialties, although earnings moved in the opposite direction to many other areas of medicine during 2025. Psychiatrists reported average compensation of approximately $331,000, with overall earnings declining by around 3% year-over-year. Despite the reduction, psychiatry continues to stand apart in one important area. Few specialties report higher levels of compensation satisfaction. While earnings growth stalled, most psychiatrists still believe they are paid fairly for the work they do. But as with most physician specialties, the biggest differences are no longer created by years of experience alone. They are increasingly shaped by productivity, practice setting and access to growing mental health demand. Psychiatry compensation remains resilient despite earnings decline The Medscape 2026 data places psychiatry in a somewhat unusual position. Compensation declined by approximately 3% during 2025, while physicians overall reported average earnings growth of roughly 3%. This means psychiatry underperformed: The physician average Core inflation of 2.7% Several procedural specialties What this means in real terms: Psychiatry experienced a temporary earnings setback. However, average compensation remains strong for a non-procedural specialty and demand for psychiatric services continues to expand across healthcare systems. The more important question is: Where do you sit within the psychiatry earnings distribution? Because compensation outcomes increasingly depend on productivity, patient demand and practice structure rather than specialty-wide growth alone. Below the psychiatry earnings range This group sits below the specialty's main compensation cluster. This typically reflects: Early-career positions Employed settings with limited productivity incentives Lower patient volumes Reduced private practice exposure What this means in real terms: You may still be earning competitively relative to many healthcare professionals. However, you currently sit below the earnings level being generated by much of the psychiatry market. Around the psychiatry earnings range This is where much of the specialty sits. Compensation here is typically driven by: Consistent patient demand Stable caseload management Standard productivity expectations A mix of outpatient and institutional work This represents the functional centre of psychiatry earnings in 2026. Above the psychiatry earnings range This is where compensation begins to separate from the wider distribution. Higher earners are often characterised by: High patient throughput Strong productivity performance Established private practice activity Additional consulting or advisory work Efficient scheduling models At this level, practice structure becomes a larger determinant of earnings than experience alone. 65% of psychiatrists feel fairly compensated One of the most striking findings in the report is that 65% of psychiatrists say they feel fairly compensated. This is substantially higher than the physician average. What this means: Psychiatry appears to have achieved something many specialties struggle with. Higher levels of compensation satisfaction despite broader healthcare pressures. Two psychiatrists earning similar incomes may still have very different experiences depending on: Administrative burden Patient complexity Staffing support Work-life balance Practice setting But overall, psychiatrists appear more satisfied with compensation than most physicians. Expectations remain positive The report shows: 44% expect compensation increases 40% expect flat pay 15% expect compensation declines What this means in real terms: Although earnings fell during 2025, psychiatrists remain relatively optimistic about future compensation. Nearly half expect earnings growth despite the recent decline. This suggests many psychiatrists view the downturn as temporary rather than structural. Incentives continue to focus on productivity Among psychiatrists eligible for incentive compensation: RVU generation remains the leading bonus driver What this means: Compensation is becoming increasingly linked to measurable clinical activity. Although psychiatry has historically relied less on productivity-based models than procedural specialties, incentive structures are becoming more common. The report also found that only 21% of psychiatrists have RVUs directly influencing base salary, significantly below the physician average. This suggests psychiatry still retains greater separation between guaranteed pay and productivity metrics than many specialties. What this means for you by experience level If you are early career (0–3 years post-consultant) At this stage, career trajectory matters more than current earnings. If you are: Below the specialty range, you are still building experience and patient volume Around the range, you are progressing in line with typical psychiatry outcomes Above the range, you may have entered a high-demand private or specialist pathway early Key point: Psychiatry offers strong long-term demand, making early career positioning particularly important. If you are mid-career (4–9 years) This is where compensation differences begin to emerge. What the report suggests: Most psychiatrists cluster around the specialty average Higher earners increasingly differentiate through productivity and private practice exposure If you are: Below the range, you sit beneath the specialty benchmark Around the range, you reflect typical psychiatry outcomes Above the range, you are benefiting from structural and productivity advantages Key insight: Practice model becomes increasingly important at this stage. If you are established (10–19 years) At this stage, earnings divergence becomes more visible. What the report shows: A stable middle exists, but a higher-income tier emerges for psychiatrists with greater productivity, specialist expertise or private practice activity. If you are: Below the range, you sit below the specialty benchmark Around the range, you align with the core distribution Above the range, you are capturing a disproportionate share of psychiatry income Key point: The financial gap between groups becomes increasingly significant. If you are senior (20+ years) At the senior level, compensation often follows one of two paths: Stable earnings supported by established patient demand and long-term practice relationships Continued growth driven by private practice expansion, specialist niches and productivity optimisation The distinction is increasingly determined by structure rather than tenure. The core message of the 2026 report The Medscape 2026 psychiatry data can be reduced to three anchors: Average compensation sits at approximately $331,000 65% feel fairly compensated 44% expect further earnings growth Taken together, the picture is clear: Psychiatry remains one of the most satisfied physician specialties despite experiencing a decline in average compensation during 2025. While earnings softened, confidence in future growth remains relatively strong. Summary If you are a psychiatrist reading this report, the key question is not whether compensation fell slightly during 2025. It is the more important question: Am I positioned to benefit from the growing demand for mental health services? Because the report makes one thing clear: Psychiatry continues to combine strong compensation with unusually high levels of physician satisfaction, but individual outcomes are increasingly determined by productivity, patient demand and practice structure rather than experience alone. Source Medscape Psychiatrist Compensation Report 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com